rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Pierre A. Morgon

Director

Company insider

Files Form 4 as: Director, Barinthus Biotherapeutics.

In numbers

Trades disclosed
19
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
1
First trade
29 Apr 2021
Last trade
9 Sep 2026
Last filed
9 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Barinthus BiotherapeuticsDirector · Biotechnology · last 9 Sep 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
9 Sep 2026filed 9 Sep 2026Barinthus BiotherapeuticsBiotechnologySEC FORM 4 Code D—10,506filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,394 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—34,328 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,394 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—34,328 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—18,604 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—19,197 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—19,516 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,174 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—18,604 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—19,197 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—19,516 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,174 at $0.00filing
9 Sep 2026filed 9 Sep 2026Barinthus BiotherapeuticsBiotechnologySEC FORM 4 Code D—10,506filing
10 Jun 2025filed 11 Jun 2025Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,174 at $0.00filing
10 May 2024filed 14 May 2024Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,516 at $0.00filing
11 May 2023filed 12 May 2023Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,197 at $0.00filing
15 Jun 2022filed 10 Feb 2023Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,604 at $0.00filing
29 Apr 2021filed 4 May 2021Barinthus Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—34,328 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Oxford Science Enterprises plcOther role · Other at Barinthus Biotherapeutics plc, filing Form 4 there in the last year
Anne M. PhillipsDirector · Director at Barinthus Biotherapeutics plc, filing Form 4 there in the last year
William EnrightChief Executive Officer · Chief Executive Officer at Barinthus Biotherapeutics plc, filing Form 4 there in the last year
Alex HammacherDirector · Director at Barinthus Biotherapeutics plc, filing Form 4 there in the last year
Robin WrightDirector · Director at Barinthus Biotherapeutics plc, filing Form 4 there in the last year